APO Research
Talk to an analyst

APO RESEARCH · REPORT

B-Cell Non-Hodgkin's Lymphoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global B-Cell Non-Hodgkin's Lymphoma Drug Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchB-Cell Non-Hodgkin's Lymphoma Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal B-Cell Non-Hodgkin's Lymphoma Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal B-Cell Non-Hodgkin's Lymphoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal B-Cell Non-Hodgkin's Lymphoma Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal B-Cell Non-Hodgkin's Lymphoma Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global B-Cell Non-Hodgkin's Lymphoma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for B-Cell Non-Hodgkin's Lymphoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for B-Cell Non-Hodgkin's Lymphoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for B-Cell Non-Hodgkin's Lymphoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the B-Cell Non-Hodgkin's Lymphoma Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the B-Cell Non-Hodgkin's Lymphoma Drug market include Acrotech Biopharma, Eagle Pharmaceuticals, Epizyme, Gilead Sciences, MundiPharma, Secura Bio, TG Therapeutics, Bayer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global B-Cell Non-Hodgkin's Lymphoma Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of B-Cell Non-Hodgkin's Lymphoma Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents B-Cell Non-Hodgkin's Lymphoma Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global B-Cell Non-Hodgkin's Lymphoma Drug market.

B-Cell Non-Hodgkin's Lymphoma Drug Segment by Company

Acrotech Biopharma

Eagle Pharmaceuticals

Epizyme

Gilead Sciences

MundiPharma

Secura Bio

TG Therapeutics

Bayer

Roche

Teva

Eisai

B-Cell Non-Hodgkin's Lymphoma Drug Segment by Type

Oral

Injection

B-Cell Non-Hodgkin's Lymphoma Drug Segment by Application

Hospital

Retail Pharmacy

Other

B-Cell Non-Hodgkin's Lymphoma Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global B-Cell Non-Hodgkin's Lymphoma Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the B-Cell Non-Hodgkin's Lymphoma Drug key companies, revenue, market share, and recent developments.

3. To split the B-Cell Non-Hodgkin's Lymphoma Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions B-Cell Non-Hodgkin's Lymphoma Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify B-Cell Non-Hodgkin's Lymphoma Drug significant trends, drivers, influence factors in global and regions.

6. To analyze B-Cell Non-Hodgkin's Lymphoma Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global B-Cell Non-Hodgkin's Lymphoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of B-Cell Non-Hodgkin's Lymphoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of B-Cell Non-Hodgkin's Lymphoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global B-Cell Non-Hodgkin's Lymphoma Drug industry.

Chapter 3: Detailed analysis of B-Cell Non-Hodgkin's Lymphoma Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of B-Cell Non-Hodgkin's Lymphoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of B-Cell Non-Hodgkin's Lymphoma Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. B-Cell Non-Hodgkin's Lymphoma Drug Industry Trends Table 2. B-Cell Non-Hodgkin's Lymphoma Drug Industry Drivers Table 3. B-Cell Non-Hodgkin's Lymphoma Drug Industry Opportunities and Challenges Table 4. B-Cell Non-Hodgkin's Lymphoma Drug Industry Restraints Table 5. Global B-Cell Non-Hodgkin's Lymphoma Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global B-Cell Non-Hodgkin's Lymphoma Drug Revenue Share by Company (2021-2026) Table 7. Global B-Cell Non-Hodgkin's Lymphoma Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global B-Cell Non-Hodgkin's Lymphoma Drug Key Company Manufacturing Base & Headquarters Table 9. Global B-Cell Non-Hodgkin's Lymphoma Drug Company, Product Type & Application Table 10. Global B-Cell Non-Hodgkin's Lymphoma Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global B-Cell Non-Hodgkin's Lymphoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2021-2026) Table 20. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Other Table 24. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2021-2026) Table 28. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2027-2032) Table 29. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Region (2021-2026) Table 32. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Region (2027-2032) Table 34. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Market Share by Country (2021-2026) Table 37. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Market Share by Country (2027-2032) Table 39. Acrotech Biopharma Company Information Table 40. Acrotech Biopharma Business Overview Table 41. Acrotech Biopharma B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Acrotech Biopharma B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 43. Acrotech Biopharma Recent Development Table 44. Eagle Pharmaceuticals Company Information Table 45. Eagle Pharmaceuticals Business Overview Table 46. Eagle Pharmaceuticals B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Eagle Pharmaceuticals B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 48. Eagle Pharmaceuticals Recent Development Table 49. Epizyme Company Information Table 50. Epizyme Business Overview Table 51. Epizyme B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Epizyme B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 53. Epizyme Recent Development Table 54. Gilead Sciences Company Information Table 55. Gilead Sciences Business Overview Table 56. Gilead Sciences B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Gilead Sciences B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 58. Gilead Sciences Recent Development Table 59. MundiPharma Company Information Table 60. MundiPharma Business Overview Table 61. MundiPharma B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. MundiPharma B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 63. MundiPharma Recent Development Table 64. Secura Bio Company Information Table 65. Secura Bio Business Overview Table 66. Secura Bio B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Secura Bio B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 68. Secura Bio Recent Development Table 69. TG Therapeutics Company Information Table 70. TG Therapeutics Business Overview Table 71. TG Therapeutics B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. TG Therapeutics B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 73. TG Therapeutics Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 78. Bayer Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Roche B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 83. Roche Recent Development Table 84. Teva Company Information Table 85. Teva Business Overview Table 86. Teva B-Cell Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Teva B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 88. Teva Recent Development Table 89. Eisai Company Information Table 90. Eisai Business Overview Table 91. Eisai B-Cell Non-Hodgkin's Lymphoma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Eisai B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio Table 93. Eisai Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. B-Cell Non-Hodgkin's Lymphoma Drug Product Image Figure 2. Global B-Cell Non-Hodgkin's Lymphoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global B-Cell Non-Hodgkin's Lymphoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global B-Cell Non-Hodgkin's Lymphoma Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Pharmacy Image Figure 14. Other Image Figure 15. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2021-2032) Figure 18. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Acrotech Biopharma
  • Eagle Pharmaceuticals
  • Epizyme
  • Gilead Sciences
  • MundiPharma
  • Secura Bio
  • TG Therapeutics
  • Bayer
  • Roche
  • Teva
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global B-Cell Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 B-Cell Non-Hodgkin's Lymphoma Drug Market Dynamics
  1. 2.1 B-Cell Non-Hodgkin's Lymphoma Drug Industry Trends
  2. 2.2 B-Cell Non-Hodgkin's Lymphoma Drug Industry Drivers
  3. 2.3 B-Cell Non-Hodgkin's Lymphoma Drug Industry Opportunities and Challenges
  4. 2.4 B-Cell Non-Hodgkin's Lymphoma Drug Industry Restraints
3 B-Cell Non-Hodgkin's Lymphoma Drug Market by Company
  1. 3.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Company Revenue Ranking in 2025
  2. 3.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Revenue by Company (2021-2026)
  3. 3.3 Global B-Cell Non-Hodgkin's Lymphoma Drug Company Ranking (2024-2026)
  4. 3.4 Global B-Cell Non-Hodgkin's Lymphoma Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global B-Cell Non-Hodgkin's Lymphoma Drug Company Product Type and Application
  6. 3.6 Global B-Cell Non-Hodgkin's Lymphoma Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 B-Cell Non-Hodgkin's Lymphoma Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 B-Cell Non-Hodgkin's Lymphoma Drug Market by Type
  1. 4.1 B-Cell Non-Hodgkin's Lymphoma Drug Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type
  5. 4.2.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2021-2032)
5 B-Cell Non-Hodgkin's Lymphoma Drug Market by Application
  1. 5.1 B-Cell Non-Hodgkin's Lymphoma Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application
  6. 5.2.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2021-2032)
6 B-Cell Non-Hodgkin's Lymphoma Drug Regional Value Analysis
  1. 6.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  7. 6.3.2 North America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  10. 6.4.2 Europe B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  16. 6.6.2 South America B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa B-Cell Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
7 B-Cell Non-Hodgkin's Lymphoma Drug Country-level Value Analysis
  1. 7.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global B-Cell Non-Hodgkin's Lymphoma Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt B-Cell Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Acrotech Biopharma
  2. 8.1.1 Acrotech Biopharma Company Information
  3. 8.1.2 Acrotech Biopharma Business Overview
  4. 8.1.3 Acrotech Biopharma B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Acrotech Biopharma B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  6. 8.1.5 Acrotech Biopharma Recent Developments
  7. 8.2 Eagle Pharmaceuticals
  8. 8.2.1 Eagle Pharmaceuticals Company Information
  9. 8.2.2 Eagle Pharmaceuticals Business Overview
  10. 8.2.3 Eagle Pharmaceuticals B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eagle Pharmaceuticals B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  12. 8.2.5 Eagle Pharmaceuticals Recent Developments
  13. 8.3 Epizyme
  14. 8.3.1 Epizyme Company Information
  15. 8.3.2 Epizyme Business Overview
  16. 8.3.3 Epizyme B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Epizyme B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  18. 8.3.5 Epizyme Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 MundiPharma
  26. 8.5.1 MundiPharma Company Information
  27. 8.5.2 MundiPharma Business Overview
  28. 8.5.3 MundiPharma B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MundiPharma B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  30. 8.5.5 MundiPharma Recent Developments
  31. 8.6 Secura Bio
  32. 8.6.1 Secura Bio Company Information
  33. 8.6.2 Secura Bio Business Overview
  34. 8.6.3 Secura Bio B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Secura Bio B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  36. 8.6.5 Secura Bio Recent Developments
  37. 8.7 TG Therapeutics
  38. 8.7.1 TG Therapeutics Company Information
  39. 8.7.2 TG Therapeutics Business Overview
  40. 8.7.3 TG Therapeutics B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 TG Therapeutics B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  42. 8.7.5 TG Therapeutics Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  60. 8.10.5 Teva Recent Developments
  61. 8.11 Eisai
  62. 8.11.1 Eisai Company Information
  63. 8.11.2 Eisai Business Overview
  64. 8.11.3 Eisai B-Cell Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eisai B-Cell Non-Hodgkin's Lymphoma Drug Product Portfolio
  66. 8.11.5 Eisai Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst